 BRIDGEWATER, N.J., Jan. 26, 2021 GLOBE NEWSWIRE -- VYNE Therapeutics Inc. Nasdaq: VYNE VYNE or the Company, today announced that it has entered into definitive agreements with institutional and accredited investors for the sale of an aggregate of 21,097,046 shares of its common stock at a purchase price of 2.37 per share in a registered direct offering priced at-the-market under Nasdaq Rules. The offering is expected to close on or about January 28, 2021, subject to the satisfaction of customary closing conditions. 